Knight Therapeutics Inc. a leading pan-American specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 9:30 a.m. ET that will be held virtually. To register, please visit the event’s registration page at the following link: Register …
Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 9:30 a.m. ET that will be held virtually. To register, please visit the event’s registration page at the following link: Register . A copy of the presentation will be available at www.gud-knight.com .
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
|Knight Therapeutics Inc.|
|Samira Sakhia||Arvind Utchanah|
|President & Chief Operating Officer||Chief Financial Officer|
|T: 514.484.4483 ext.122||T. 514.484.4483 ext. 115|
|F: 514.481.4116||F. 514.481.4116|
|Email: firstname.lastname@example.org||Email: email@example.com|
|Website: www.gud-knight.com||Website: www.gud-knight.com|
News Provided by GlobeNewswire via QuoteMedia